Harvard-linked Sana Biotechnology will raise as much as $397m if it floats at the upper end and underwriters take up the greenshoe option.

Sana Biotechnology, a US-based stem cell medicines developer based on research at Harvard University, has set its price range at $20 to $23 and plans to issue 15 million shares in its IPO on the Nasdaq Global Select Market. The company has also allocated an additional 2.5 million shares to the overallotment option. It stands…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.